A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine

NCT03806595 | Completed Phase 1

• 1 other identifier: H18-03801
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Headaches in children are very common and are a source of significant distress for the patient and their family. Migraines are the most common headache disorder in children and are associated with episodic pain and other symptoms such as nausea and sensitivity to light and sound that can impair a child's ability to participate in daily activities and lead to missed school or parental missed work. When home treatment fails to relieve symptoms, children often seek care in the emergency department (ED) where a limited number of treatment options exist; while largely effective, these rescue treatments currently all require needle insertion of an intravenous line, take time to administer, result in prolonged ED stays, and have potential unpleasant side effects. In adult patients, a number of studies suggest that lidocaine, a local anesthetic administered intranasally, may provide relief of migraine and migraine-like headache pain in minutes. This approach has the benefit of working quickly, not requiring a needle, and having fewer side effects as the medication acts locally on nerves in the nose. Intranasal lidocaine has not yet been studied in children for this purpose. This study will compare the use of intranasal lidocaine to placebo. The goal of this pilot study is to provide information to inform the sample size calculation for the definitive randomized controlled trial that will aim to measure the efficacy of intranasal lidocaine as an analgesic option for children age 7 years and older who present to the Pediatric ED with a chief complaint of migraine or post traumatic headache with migraine-like features. Secondary objectives will be to report on the frequency and severity of rebound headache between the two treatment groups, adverse events of the study drug, as well as the impact on healthcare utilization measures.The investigators hypothesize that children receiving intranasal lidocaine will have faster and more effective pain recovery compared to children receiving placebo and will be less likely to require the standard therapy for migraine headache. Given very few side effects reported in adult studies and the relatively benign nature of those reported, the investigators do not expect any major safety concerns in the study. It is also hypothesized that intranasal lidocaine will lead to shorter ED visits, thus reducing use of staff and hospital resources and saving money for the healthcare system as a whole.

Conditions

Migraine in Children; Posttraumatic Headache

Outcome Measures

Primary Outcomes (1)

• Change in migraine pain

  The primary outcome measure will be the proportion of subjects with numeric pain scores of \< 4 out of 10 on a verbal rating scale (range 0 -10 with increasing severity, i.e. 0 = no pain and 10 = most severe pain).Treatment success is defined as a score of 3 or less at the two time points. This will be recorded for each patient during the study timeframe, until study completion.

  Pain scores will be measured at 30 and 60 minutes post intranasal administration of either the study drug or placebo.

Secondary Outcomes (4)

• Rebound headache

  Pain scores will be recorded at 60 minutes, 24 hours, and within 48-72 hours post intranasal therapy.

• Emergency department length of stay

  The emergency department length of stay will be ascertained from the medical record within 24 hours of the participant's visit.

• Proportion of participants discharged vs. admitted from the emergency department (emergency department disposition)

  Disposition will be ascertained from the medical record within 24 hours of the participant's ED visit.

• Proportion of participants with a return visit to the emergency department within 72 hours of discharge.

  Within 3 days from index visit.

Study Arms (2)

Intranasal lidocaine

EXPERIMENTAL

1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.

Drug: Lidocaine 2% Injectable Solution

Intranasal normal saline

PLACEBO COMPARATOR

1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.

Drug: Normal Saline Flush, 0.9% Injectable Solution

Interventions

Lidocaine 2% Injectable Solution DRUG

The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.

Intranasal lidocaine

Normal Saline Flush, 0.9% Injectable Solution DRUG

The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.

Intranasal normal saline

Eligibility Criteria

• Age: 7 Years - 16 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Children aged 7-16 years
• Migraine headache fulfilling Irma's criteria:
• Headache lasting 1-72 hours with at least 4 out of 6 of the following features:
• Moderate to severe episode of impaired daily activities
• Focal localization of headache
• Pulsatile description
• Nausea or vomiting or abdominal pain
• Photophobia, phonophobia, or avoidance of light and noise, or
• Symptoms increasing with activity or resolving by rest.
• OR:
• Post-traumatic headache as per ICHD-3 (beta edition) definition with migraine-like features (see above):
• A) Any headache fulfilling criteria C and D
• B) Traumatic injury to the head has occurred
• C) Headache is reported to have developed within 7 days after one of the following:
• i. The injury to the head, ii. Regaining of consciousness following the injury to the head, iii. Discontinuation of medication(s) that impair ability to sense or report headache following the injury to the head

You may not qualify if:

• Families not providing informed consent or assent, where appropriate
• History of acute trauma or seizure in the preceding 24 hours
• Clinical suspicion of or known intracranial pathology or underlying central nervous system disease
• Headache associated with fever or meningismus
• Known allergy/sensitivity to lidocaine

Sponsors & Collaborators

• University of British Columbia: lead

Study Sites (1)

BC Children's Hospital

Vancouver, British Columbia, V6H 3N1, Canada

Location

MeSH Terms

Conditions

Post-Traumatic Headache

Interventions

Lidocaine

Condition Hierarchy (Ancestors)

Headache Disorders, Secondary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Officials

• Garth Meckler, MD

  University of British Columbia

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Pediatric Emergency Medicine Division Head

Study Record Dates

• First Submitted: November 23, 2018
• First Posted: January 16, 2019
• Study Start: July 3, 2019
• Primary Completion: December 3, 2020
• Study Completion: December 3, 2020
• Last Updated: April 28, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)